Experienced in Acute Myelomonocytic Leukemia

Dr. Jeffrey P. Letzer

Parkview Health System Inc
Fort Wayne, IN
Experienced
in Acute Myelomonocytic Leukemia
Specialties:Hematology Oncology | Hematology | Oncology
Accepting New Patients
Offers Telehealth
OverviewInsuranceLocationsClinical Research

Overview

Jeffrey Letzer is a Hematologist Oncology specialist and a Hematologist in Fort Wayne, Indiana. Dr. Letzer and is rated as an Experienced provider by MediFind in the treatment of Acute Myelomonocytic Leukemia. His top areas of expertise are Lung Cancer, Small Cell Lung Cancer (SCLC), Large-Cell Immunoblastic Lymphoma, Thrombocytopenia, and Bone Marrow Aspiration. Dr. Letzer is currently accepting new patients.

His clinical research consists of co-authoring 2 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in MI
Hospital Affiliations
Promedica Coldwater Regional Hospital
Parkview Whitley Hospital
Parkview Regional Medical Center
Parkview Huntington Hospital
Parkview Wabash Hospital, Inc
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Blue Cross Blue Shield
  •  Ambetter
  •  McLaren Health
  •  CareSource
  •  Humana

Locations

PARKVIEW HEALTH SYSTEM INC
11050 Parkview Circle Dr, Fort Wayne, IN 46845
833-724-8326

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: February 25, 2025
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
Randomized Study of Erlotinib vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: February 25, 2025
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active_not_recruiting
Publish Date: February 25, 2025
Intervention Type: Other, Procedure, Biological
Study Drug: Nivolumab
Study Phase: Phase 3
Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma
Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: February 24, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Bendamustine Hydrochloride, Cyclophosphamide, Doxorubicin Hydrochloride, Lenalidomide, Obinutuzumab, Prednisone, Umbralisib, Vincristine Sulfate
Study Phase: Phase 2
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: February 10, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
A Randomized Phase II/III Trial of Novel Therapeutics Versus Azacitidine in Newly Diagnosed Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS), Age 60 or Older LEAP: Less-Intense AML Platform Trial
A Randomized Phase II/III Trial of Novel Therapeutics Versus Azacitidine in Newly Diagnosed Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS), Age 60 or Older LEAP: Less-Intense AML Platform Trial
Enrollment Status: Completed
Publish Date: January 16, 2025
Intervention Type: Drug, Biological, Other
Study Drugs: Azacitidine, Cytarabine, Decitabine, Midostaurin, Nivolumab
Study Phase: Phase 2/Phase 3
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: January 03, 2025
Intervention Type: Drug, Biological, Procedure, Other, Radiation
Study Drugs: Brentuximab, Dacarbazine, Doxorubicin, Filgrastim, Nivolumab, Pegfilgrastim, Vinblastine
Study Phase: Phase 3
Randomized Phase III Trial of Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
Randomized Phase III Trial of Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
Enrollment Status: Active_not_recruiting
Publish Date: November 29, 2024
Intervention Type: Other, Drug
Study Drugs: Bortezomib, Carfilzomib, Dexamethasone, Lenalidomide
Study Phase: Phase 3
A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination With BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients With Molecular Evidence of Disease
A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination With BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients With Molecular Evidence of Disease
Enrollment Status: Active_not_recruiting
Publish Date: July 08, 2024
Intervention Type: Drug, Other
Study Drugs: Bosutinib, Dasatinib, Nilotinib, Nilotinib Hydrochloride Monohydrate, Ruxolitinib, Ruxolitinib Phosphate
Study Phase: Phase 2
A Phase II/III Trial of Neoadjuvant FOLFOX With Selective Use of Combined Modality Chemoradiation Versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection With Total Mesorectal Excision (PROSPECT)
A Phase II/III Trial of Neoadjuvant FOLFOX With Selective Use of Combined Modality Chemoradiation Versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection With Total Mesorectal Excision (PROSPECT)
Enrollment Status: Active_not_recruiting
Publish Date: February 02, 2024
Intervention Type: Procedure, Other, Drug
Study Phase: Phase 2/Phase 3
View 9 Less Clinical Trials

2 Total Publications

An Expanded Treatment Protocol of Panobinostat Plus Bortezomib and Dexamethasone in Patients With Previously Treated Myeloma.
An Expanded Treatment Protocol of Panobinostat Plus Bortezomib and Dexamethasone in Patients With Previously Treated Myeloma.
Journal: Clinical lymphoma, myeloma & leukemia
Published: September 18, 2017
Similar Doctors
Expertise in
18
conditions
Dr. Sreenivasa R. Nattam
Hematology Oncology | Oncology | Hematology
Expertise in
18
conditions
Dr. Sreenivasa R. Nattam
Hematology Oncology | Oncology | Hematology

Fort Wayne Medical Oncology And Hematology Inc

2514 E Dupont Rd, Suite 100, 
Fort Wayne, IN 
 (0.9 mi)
260-484-8830
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Sreenivasa Nattam is a Hematologist Oncology specialist and an Oncologist in Fort Wayne, Indiana. Dr. Nattam and is rated as an Advanced provider by MediFind in the treatment of Acute Myelomonocytic Leukemia. His top areas of expertise are Childhood Iron Deficiency Anemia, Familial Pancreatic Cancer, Paget Disease of the Breast, Familial Colorectal Cancer, and Bone Marrow Aspiration. Dr. Nattam is currently accepting new patients.

Expertise in
21
conditions
Dr. Yasolatha Nalamolu
Hematology Oncology | Hematology | Oncology
Expertise in
21
conditions
Dr. Yasolatha Nalamolu
Hematology Oncology | Hematology | Oncology

Fort Wayne Medical Oncology And Hematology Inc

7910 W Jefferson Blvd, Suite 108, 
Fort Wayne, IN 
 (12.9 mi)
260-484-8830
Languages Spoken:
English, Hindi, Telugu
See accepted insurances
Accepting New Patients

Yasolatha Nalamolu is a Hematologist Oncology specialist and a Hematologist in Fort Wayne, Indiana. Dr. Nalamolu and is rated as a Distinguished provider by MediFind in the treatment of Acute Myelomonocytic Leukemia. Her top areas of expertise are Thrombocytopenia, Paget Disease of the Breast, Childhood Iron Deficiency Anemia, and Hemangioma Thrombocytopenia Syndrome. Dr. Nalamolu is currently accepting new patients.

Expertise in
17
conditions
Dr. Gary R. Gize
Hematology Oncology | Hematology | Oncology
Expertise in
17
conditions
Dr. Gary R. Gize
Hematology Oncology | Hematology | Oncology

Fort Wayne Medical Oncology And Hematology Inc

516 E Maumee St, 
Angola, IN 
 (31.4 mi)
260-484-8830
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Gary Gize is a Hematologist Oncology specialist and a Hematologist in Angola, Indiana. Dr. Gize and is rated as a Distinguished provider by MediFind in the treatment of Acute Myelomonocytic Leukemia. His top areas of expertise are Adult Immune Thrombocytopenia, Hemangioma Thrombocytopenia Syndrome, Thrombocytopenia, Colorectal Cancer, and Bone Marrow Aspiration. Dr. Gize is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile